ACRV · Acrivon Therapeutics, Inc. · Metrics
Market Cap
$72.60M
Shares
42.85M
Volume · Oct 19
122.95K
Avg daily vol (3M)
316.11K
ACRV metrics
62 of 115 screener metrics currently available.
Market overview
2 metricsShare price
$1.69
Market cap
$72.60M
Price action
20 metricsPrice change (1W)
-11.1%
Price change (30D)
-15.9%
Price change (3M)
-2.9%
Price change (6M)
-9.1%
Price change (YTD)
-29.9%
Price change (1Y)
-6.6%
Trailing year
Price change (5Y)
—
52-week high
$3.01
52-week low
$1.29
Change from 52-week high
-43.9%
Change from 52-week low
+31.0%
Annualized volatility
89.3%
Annualized volatility (3M)
71.8%
Beta
2.1
RSI (14D)
37.5
Price vs SMA 50
-14.5%
Price vs SMA 200
-5.4%
Avg volume (3M)
316,099
Relative volume
0.4
Average dollar volume
$600,084
Company
3 metricsSector
Healthcare
Industry
Biotechnology
Shares outstanding
42.85M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
0.8
reciprocal yield 119.4%
FCF yield
-88.3%
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-102.2%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-05-26
Profitability
9 metricsGross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
—
Operating profit (TTM)
−$78.37M
Net income (TTM)
−$74.22M
Trailing 12 months
Diluted EPS (TTM)
$-1.88
FCF margin
—
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
—
Year over year
Net income growth YoY
—
Revenue (TTM)
—
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+8.8%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-85.6%
Return on assets
-74.9%
Debt / equity
0.0
Current ratio
8.0
EBITDA (TTM)
—
Free cash flow (TTM)
−$64.14M
Quick ratio
8.0
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$89.96M
Latest balance sheet
Cash & equivalents
$41.42M
Total assets
$99.09M
Total debt
$0
Cash flow & spend
7 metricsOperating cash flow (TTM)
−$62.92M
Capital expenditures (TTM)
$1.22M
R&D (TTM)
$57.40M
SG&A (TTM)
—
Stock compensation (TTM)
$11.40M
R&D / revenue
—
Stock compensation / revenue
—
Ownership (13F)
3 metrics13F filers
46
13F filer change QoQ
+2
Institutional ownership
49.9%
Short interest
3 metricsShort interest
3.8%
Latest settlement · 4.4 days to cover
Days to cover
4.4d
Short-squeeze score
55 / 100
Insider activity
2 metricsNet insider buying (90D)
−$39,383
Insider-sentiment score
30 / 100
Risk flags
1 metricsGoing concern
—